NuVasive Given Buy Rating at Jefferies Group (NUVA)
NuVasive (NASDAQ:NUVA)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Wednesday. They currently have a $48.00 price objective on the stock, up from their previous price objective of $45.00. Jefferies Group’s price objective would suggest a potential upside of 25.61% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Barclays reiterated an “equal weight” rating on shares of NuVasive in a research note on Wednesday. They now have a $42.00 price target on the stock, up previously from $40.00. Separately, analysts at Goldman Sachs upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 25th. Finally, analysts at Needham & Company LLC downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, May 21st. They now have a $40.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $41.03.
Shares of NuVasive (NASDAQ:NUVA) traded up 9.01% during mid-day trading on Wednesday, hitting $38.215. The stock had a trading volume of 1,729,333 shares. NuVasive has a 1-year low of $22.44 and a 1-year high of $39.89. The stock has a 50-day moving average of $34.49 and a 200-day moving average of $35.40. The company’s market cap is $1.781 billion.
NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.03. The company had revenue of $190.70 million for the quarter, compared to the consensus estimate of $177.50 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. Analysts expect that NuVasive will post $1.09 EPS for the current fiscal year.
NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.